Cidofovir as a potential antiviral agent against Monkeypox: A systematic review
Keywords:
Monkeypox, antiviral, cidofovirAbstract
Monkeypox outbreaks in various countries are a public health problem. This disease must be managed and treated more as an unnoticed or rare medical illness. Cidofovir targets various DNA viruses, including poxviruses. In this study, cidofovir was tested for monkeypox antiviral activity. This study used ProQuest, EBSCOhost, JSTOR, PubMed, and Taylor & Francis. The search included all available material up till November 23, 2022. The titles and abstracts were assessed for relevance. The analysis included English-language studies on cidofovir's monkeypox treatment efficacy. Based on inclusion criteria, 10 of 326 studies were chosen. Five in vitro studies, three in vivo studies, one case report, and one observational study were published between 2002 and 2022. All studies have shown that cidofovir inhibits viral replication. After monkeypox exposure, cidofovir improved symptoms and reduced the viral load. This effect was substantial when cidofovir was given early in the disease. The intervention had no signs or symptoms of toxicity, indicating good safety. Cidofovir was effective against monkeypox.References
Guarner J, Rio C del, Malani PN. Monkeypox in 2022-what clinicians need to know. JAMA. 2022;328:139–40.
Silva EJNL, Prado MC, Soares DN, Hecksher F, Martins JNR, Fidalgo TKS. The effect of ozone therapy in root canal disinfection: a systematic review. Int Endod J. 2020;53:317–32.
Frenois-Veyrat G, Gallardo F, Gorgé O, Marcheteau E, Ferraris O, Baidaliuk A, et al. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations. Nat Microbiol. 2022; 7:1951-5.
Alkhalil A, Strand S, Mucker E, Huggins JW, Jahrling PB, Ibrahim SM. Inhibition of monkeypox virus replication by RNA interference. Virol J. 2009;6:1–10.
Vigne S, Duraffour S, Andrei G, Snoeck R, Garin D, Crance JM. Inhibition of vaccinia virus replication by two small interfering RNAS targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrob Agents Chemother. 2009; 53:2579-88.
Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox, and other orthopoxvirus infections. Antivir Res. 2003;57:13–23.
Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother. 2002;46:1329-35.
Schultz DA, Sagartz JE, Huso DL, Buller RML. Experimental infection of an African dormouse (Graphiurus Kelleni) with Monkeypox virus. Virology. 2009;383:86-92.
Stittelaar KJ, Neyts J, Naesens L, Amerongen G van, Lavieren RF van, Holý A, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006;439:745-8.
Fabrizio C, Bruno G, Cristiano L, Buccoliero GB. Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome. Infection. 2023;51:519-22.
Mondi A, Gagliardini R, Mazzotta V, Vita S, Carletti F, Pinnetti C, et al. Clinical experience with use of oral tecovirimat or intravenous cidofovir for the treatment of Monkeypox in an Italian reference hospital. J Infect. 2023;86:66–117.
Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol. 2010;84:3909–20.